Summary of Rain Oncology Inc. Q2 2023 Earnings Call

1Key Financial Results and Metrics

Net Loss: $22.1 million for Q2 2023, compared to $17.6 million in Q2 2022, primarily due to increased clinical trial costs and personnel expenses.

General and Administrative Expenses: Increased to $5.4 million from $3.5 million year-over-year, driven by launch preparation costs and higher personnel and consulting fees.

Restructuring Charges: $2.8 million related to workforce reduction.

Cash Position: As of June 30, 2023, Rain had $86.3 million in cash and equivalents, projected to last until the end of 2026 without additional financing.

2Strategic Updates and Business Highlights

Milademetan Phase 3 Trial: The trial did not meet its primary endpoint, leading to the suspension of the MANTRA-2 study. The company plans to close this study to conserve capital.

Future Data Presentations: Final data from the MANTRA Phase 3 study and updated data from the MANTRA-2 Phase 2 study are expected in Q4 2023.

Corporate Development: Rain is exploring opportunities to license or acquire clinical-stage programs, focusing on precision oncology strategies across both small and large molecules.

3Forward Guidance and Outlook

Cost Management: The company has implemented cost-saving measures, including a reduction in workforce, which is expected to significantly lower cash burn in the second half of 2023.

Cash Runway: The current cash position is anticipated to support operations through the end of 2026, excluding any potential corporate transactions or financing.

4Bad News, Challenges, or Points of Concern

Clinical Setbacks: The failure of the milademetan Phase 3 trial is a significant setback, leading to the suspension of related studies and raising concerns about the viability of the drug.

Operational Streamlining: While cost-cutting measures are being implemented, the reduction in workforce and suspension of studies may impact the company’s ability to innovate and progress in its pipeline.

5Notable Q&A Insights

Future of Milademetan: The management indicated that there are no current plans to advance the milademetan program or the RAD52 asset.

Cash Runway Guidance: The guidance does not factor in potential new deals or financing, emphasizing a conservative approach moving forward.

Opportunities for New Assets: Management is open to various modalities and is actively reviewing potential licensing opportunities, focusing on leveraging their clinical expertise. Overall, Rain Oncology is navigating a challenging period following the disappointing results of its key clinical trial while strategically repositioning itself to explore new opportunities in the oncology space.